e18511 Background: We previously reported the use of fludarabine, rituximab and
cyclophosphamide as a nonmyeloablative conditioning for lymphomas (Khouri et al, Blood …

Over the last 30 years, BEAM has been the most widely used conditioning regimen before
autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with Hodgkin …

We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in
patients with relapsed/refractory lymphoma and residual disease after salvage therapy …

We have read the paper by Chantepie et al. 1 evaluating safety of benadamustine-based
conditioning prior to autologous stem cell transplantation (ASCT) with great interest. Authors …

Background Bendamustine is a chemotherapeutic agent that has shown broad activity in
patients with lymphoid malignancies. It contains both alkylating and nucleoside analog …

Background We previously reported the use of BFR, with phase 1 escalating daily doses of
70, 90, 110, or 130 mg/m 2 of bendamustine daily x 3 days prior to transplantation without …

Background Autologous hematopoietic cell transplant (autoHCT) is the standard of care for
relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and Hodgkin Lymphoma (HL) …

Single-agent high-dose melphalan (Mel) followed by autologous stem cell transplantation
(ASCT) remains a standard of care in eligible patients with multiple myeloma (MM), and …

Abstract Abstract 1933 Introduction: Bendamustine is a bifunctional alkylating agent with low
toxicity that produces both single-and double-strand breaks in DNA, and shows only partial …

Bendamustine has shown a favorable safety profile when included in chemotherapy
regimens for several types of lymphoma, including CLL. This study investigated the long …